Equities

Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Actions
  • Price (USD)3.31
  • Today's Change-0.16 / -4.61%
  • Shares traded298.36k
  • 1 Year change-55.27%
  • Beta3.5333
Data delayed at least 15 minutes, as of Apr 03 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

  • Revenue in USD (TTM)0.00
  • Net income in USD-32.94m
  • Incorporated2007
  • Employees28.00
  • Location
    Zynerba Pharmaceuticals Inc80 W. Lancaster Avenue, Suite 300DEVON 19333United StatesUSA
  • Phone+1 (484) 581-7505
  • Fax+1 (302) 655-5049
  • Websitehttp://zynerba.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vivakor inc594.09k-561.45k74.55m3.00--137.57--125.49-0.0028-0.00280.00390.00190.1739--12.30---19.76-7.60---14.57100.0095.87-113.67-73.35---0.50690.9305---42.9823.70131.35------
AIM ImmunoTech Inc330.00k-9.95m75.42m31.00--1.27--228.54-6.57-6.570.19522.270.0175--7.3310,645.16-52.85-53.85-69.82-63.14-190.30-391.35-3,015.76-4,751.55---18.800.3277---16.0219.60-18.82---35.53--
Vermillion, Inc.4.15m-14.67m75.88m43.00--6.41--18.28-0.1825-0.18250.05120.12160.276745.895.0396,558.14-97.78-92.02-122.02-115.6820.429.04-353.32-556.164.53--0.1032---2.183.540.5945---18.85--
Ampio Pharmaceuticals Inc0.00-13.63m77.52m23.00--12.02-----0.1062-0.10620.000.04060.00----0.00-97.25-55.21-121.90-63.40------------0.00-------140.10---69.74--
Five Prime Therapeutics Inc14.87m-137.20m77.88m87.00--0.5009--5.24-3.92-3.920.42544.270.0545--3.24170,965.50-50.29-13.17-55.42-14.93-----922.43-47.39----0.00---70.17-5.012.31--1.57--
Zynerba Pharmaceuticals Inc0.00-32.94m77.97m28.00--1.02-----1.52-1.520.003.260.00----0.00-42.48-52.88-49.42-61.06-------37,836.07----0.00---100.00--17.46--45.68--
Axcella Health Inc0.00-59.08m78.38m64.00--1.30-----2.88-2.880.002.60------0.00-------------------36.330.2925-------63.11------
TFF Pharmaceuticals Inc0.00-36.68m78.42m4.00--2.80-----2.00-2.000.001.500.00----0.00-59.97---62.44--------------0.00-------702.43------
SCYNEXIS Inc121.00k-53.71m78.91m27.00--6.12--652.13-0.984-0.9840.00220.13240.0022----4,481.48-97.37-58.31-114.97-67.40-----44,388.43-13,016.97---11.420.4719---52.92-37.37-330.78------
Integrity Applications Inc140.26k-35.33m79.74m19.00------568.54-3.15-3.150.0012-0.00530.0633--1.857,382.11-191.79-176.63---629.40-----3,029.77-1,748.820.5332-11.56-----92.62---238.46---39.13--
Champions Oncology Inc31.09m-180.00k80.24m115.00--25.12140.282.58-0.0236-0.02362.500.26872.39--7.39270,373.90-1.39-72.35-3.66-225.1047.7138.57-0.5789-38.44----0.0528--33.7218.57108.67--28.94--
ContraFect Corp0.00-12.79m80.34m24.00--5.17-----1.55-1.550.001.010.00----0.00-37.70-63.28-49.18-73.59------------0.00------66.05------
Emmaus Life Sciences Inc7.46m-32.89m80.61m6.00------10.81-5.26-5.260.5912-0.36760.242--7.60---111.05-249.68-256.40-1,538.9085.1645.34-458.86-1,668.251.26-0.98320.07--923.7458.65-34.95------
Aravive Inc4.75m-18.22m80.64m17.00--1.17--16.97-1.58-1.580.41024.600.0627--3.06279,588.30-24.04-57.23-25.18-64.49-----383.29-846.68----0.00--246.68--76.13------
Marker Therapeutics Inc213.19k-21.43m81.43m28.00--1.81--381.97-0.4701-0.47010.00470.96470.0039--2.597,613.93-39.50-206.20-41.32-312.10-----10,051.11-51,741.45----0.00--3.50--85.52------
Data as of Apr 03 2020. Currency figures normalised to Zynerba Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

32.70%Per cent of shares held by top holders
HolderShares% Held
ETF Managers Group LLCas of 31 Dec 20192.04m8.78%
The Vanguard Group, Inc.as of 31 Dec 20191.63m7.02%
BlackRock Fund Advisorsas of 31 Dec 20191.39m5.97%
Portolan Capital Management LLCas of 31 Dec 2019436.26k1.88%
Morgan Stanley & Co. LLCas of 31 Dec 2019417.29k1.80%
SSgA Funds Management, Inc.as of 31 Dec 2019403.69k1.74%
Zeke Capital Advisors LLCas of 31 Dec 2019402.21k1.73%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2019316.07k1.36%
Horizons ETFs Management (Canada), Inc.as of 31 Dec 2019279.90k1.21%
Geode Capital Management LLCas of 31 Dec 2019279.50k1.21%
More ▼
Data from 31 Dec 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.